<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tesfaye, Solomon</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Challenges of Pharmaceutical Management of Painful Diabetic Peripheral Neuropathy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-23</style></pages><abstract><style  face="normal" font="default" size="100%">Diabetic peripheral neuropathy (DPN) affects up to 50% of patients with diabetes and is a major cause of morbidity and increased mortality. Its clinical manifestations, which include painful neuropathic symptoms and insensitivity, increase the risk for burns, injuries, and foot ulceration [Tesfaye S, Selvarajah D. Diabetes Metab Res Rev 2012]. This article discusses findings from recent studies on pharmaceutical agents used to treat DPN.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>